Drug intelligence / Profile preview

CMB-B01

Development stage: Unknown
Lead developer: Chung Mei Biopharma
Modality: Small Molecules

Overview

CMB-B01 is a small molecule drug candidate developed by Chung Mei Biopharma for the treatment of advanced melanoma. The drug was originally derived from cancer research conducted at Academia Sinica, with its manufacturing and quality control processes developed by the Development Center for Biotechnology. CMB-B01 acts as an anti-inflammatory and anti-tumor agent by inhibiting the COX-2 pathway. This inhibition leads to a reduction in prostaglandin E2 (PGE2) levels, decreased activity of the NF-κB p65 subunit, and lower production of nitric oxide (NO). The US FDA cleared the Investigational New Drug (IND) application (IND 133599) for CMB-B01 in March 2017, and the company has since been preparing for clinical trials in Taiwan.

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)RELA (Nuclear Factor Kappa B Subunit p65)NO2- (Nitrite)PGE2 (Prostaglandin E2)

Beyond the preview

Go deeper on CMB-B01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMB-B01.